author-photo

Mercidita T. Navarro

Genentech

11

Papers

106

Citations

Citation Trend

Filter By

Papers (10) Sort By

Journal Conference Others

DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha‐2a/ribavirin in HCV genotypes 1 or 4

2015 Liver International
Show All
- Source
- Cite
- Save
Citations (27)
Effect of meal and antisecretory agents on the pharmacokinetics of danoprevir/ritonavir in healthy volunteers.

2014 Journal of Pharmacy and Pharmacology
Show All
- Source
- Cite
- Save
Citations (7)
Effect of Ritonavir‐Boosted Danoprevir, a Potent Hepatitis C Virus Protease Inhibitor, on the Pharmacokinetics of Methadone in Healthy Subjects Undergoing Methadone Maintenance Therapy

2014 Pharmacotherapy
Show All
- Source
- Cite
- Save
Citations (2)
Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.

2013 Gastroenterology
Show All
- Source
- Cite
- Save
Citations (25)
Pharmacokinetics of a three-way drug interaction between danoprevir, ritonavir and the organic anion transporting polypeptide (OATP) inhibitor ciclosporin.

2013 Clinical Pharmacokinectics
Show All
- Source
- Cite
- Save
Citations (15)
1191 LOW RATE OF ON-TREATMENT RESISTANCE TO DANOPREVIR BOOSTED BY RITONAVIR (DNVR) COMBINED WITH PEG-IFNa-2A/RIBAVIRIN: 12 WEEK INTERIM ANALYSIS FROM DAUPHINE STUDY

2012 Journal of Hepatology
Show All
- Source
- Cite
- Save
Citations (4)
1190 DANOPREVIR PLUS PEG-IFNa-2A/RIBAVIRIN FOR 12 WEEKS RESULTS IN DURABLE VIRAL SUPPRESSION AND LOW RATES OF RESISTANCE THROUGHOUT TREATMENT AND FOLLOW-UP: RESULTS FROM THE ATLAS STUDY

2012 Journal of Hepatology
Show All
- Source
- Cite
- Save
Citations (0)
Pharmacokinetics and Safety of Coadministered Oseltamivir and Rimantadine in Healthy Volunteers: An Open‐Label, Multiple‐Dose, Randomized, Crossover Study

2012 The Journal of Clinical Pharmacology
Show All
- Source
- Cite
- Save
Citations (1)
1192 HIGH SUSTAINED VIROLOGICAL RESPONSE RATES WITH RESPONSE-GUIDED DANOPREVIR PLUS PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN IN TREATMENT-NAIVE, HCV GENOTYPE 1 PATIENTS: ATLAS STUDY FINAL RESULTS

2012 Journal of Hepatology
Show All
- Source
- Cite
- Save
Citations (4)
1177 RAPID AND SUSTAINED ACHIEVEMENT OF UNDETECTABLE HCV RNA DURING TREATMENT WITH RITONAVIR-BOOSTED DANOPREVIR/PEG-IFNa-2A/RBV IN HCV GENOTYPE 1 OR 4 PATIENTS: DAUPHINE WEEK 12 INTERIM ANALYSIS

2012 Journal of Hepatology
Show All
- Source
- Cite
- Save
Citations (18)